Accelerated Approval For PCSK9 Inhibitors Not Up For Discussion, FDA Tells Panel
Executive Summary
FDA asked its advisory committee not to discuss accelerated approval for Sanofi/Regeneron's Praluent and Amgen's Repatha; panelists wanted to discuss the idea anyway, however, given uncertainty around the reliability of LDL-cholesterol as a surrogate.
You may also be interested in...
How Much Is A Priority Review Worth? $67.5 Million, Sanofi/Regeneron Say
Companies’ decision to purchase and redeem BioMarin’s priority review voucher for their PCSK9 inhibitor alirocumab sets the first public benchmark for a voucher’s value and shows the potential advantages to be gained for sponsors in a race to market.
Wary Of Surrogates, Payers Seek Outcomes Data For PCSK9 Class
Regeneron/Sanofi and Amgen stress the strengths of the Phase III PCSK9 development programs at the American College of Cardiology annual meeting. The mechanism of action holds appeal, but development is taking place at a time of skepticism about surrogate CV markers, following failed trials of other drugs.
Clinical Trial Diversity Requires Sponsors Work With An Assortment Of Patient Advocates, Community Organizations
US FDA oncology officials are concerned that the entities sponsors are consulting in developing and implementing clinical trial diversity plans are not sufficiently diverse themselves and do not represent patients in underserved communities.